Targeting the PI3K/Akt/mTOR Pathway - Beyond Rapalogs

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216

The phosphoinositide 3-kinase pathway

Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621

Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor

Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., Arden, K. C., Blenis, J., & Greenberg, M. E. (1999) · Cell · doi:10.1016/s0092-8674(00)80595-4 · Cited by 5,594

Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma

Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., Staroslawska, E., Sosman, J., McDermott, D., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,647

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330

Defining the role of mTOR in cancer

Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833

MicroRNA-21 Regulates Expression of the PTEN Tumor Suppressor Gene in Human Hepatocellular Cancer

Meng, F., Henson, R., Wehbe–Janek, H., Ghoshal, K., Jacob, S. T., & Patel, T. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.05.022 · Cited by 2,773

mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt

O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561

Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery

Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., & Mills, G. B. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1902 · Cited by 2,185

Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization

Diehl, J. A., Cheng, M., Roussel, M. F., & Sherr, C. J. (1998) · Genes & Development · doi:10.1101/gad.12.22.3499 · Cited by 2,130

Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome

Liaw, D., Marsh, D. J., Li, J., Dahia, P. L. M., Wang, S. I., Zheng, Z., Bose, S., Call, K. M., Tsou, H. C., Peacoke, M., et al. (1997) · Nature Genetics · doi:10.1038/ng0597-64 · Cited by 2,091

Phosphatidylinositol-3-OH kinase direct target of Ras

Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. J., Waterfield, M. D., & Downward, J. (1994) · Nature · doi:10.1038/370527a0 · Cited by 1,954

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

Carracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., Egia, A., Sasaki, A. T., Thomas, G., Kozma, S. C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34739 · Cited by 1,381

PHOSPHOINOSITIDE KINASES

Fruman, D. A., Meyers, R. E., & Cantley, L. C. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.481 · Cited by 1,355

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer

Carpten, J. D., Faber, A. L., Horn, C., Donoho, G. P., Briggs, S. L., Robbins, C. M., Hostetter, G., Boguslawski, S., Moses, T. Y., Savage, S., et al. (2007) · Nature · doi:10.1038/nature05933 · Cited by 1,292

Phosphorylation and Functional Inactivation of TSC2 by Erk

Ma, L., Chen, Z., Erdjument-Bromage, H., Tempst, P., & Pandolfi, P. P. (2005) · Cell · doi:10.1016/j.cell.2005.02.031 · Cited by 1,268

Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis

Cully, M., You, H., Levine, A. J., & Mak, T. W. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1819 · Cited by 1,233

The lipid phosphatase activity of PTEN is critical for its tumor supressor function

Myers, M. P., Pass, I., Batty, I. H., Van der Kaay, J., Stolarov, J. P., Hemmings, B. A., Wigler, M. H., Downes, C. P., & Tonks, N. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.23.13513 · Cited by 1,168

Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors

Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2010) · Cancer · doi:10.1002/cncr.25219 · Cited by 1,139

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

Maira, S.-M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., Fritsch, C., Brachmann, S., Chène, P., De Pover, A., Schoemaker, K., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0017 · Cited by 1,134

Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2

Feldman, M. E., Apsel, B., Uotila, A., Loewith, R., Knight, Z. A., Ruggero, D., & Shokat, K. M. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000038 · Cited by 1,082

An integrative genomic and proteomic analysis of pik3ca, pten, and akt mutations in breast cancer.

Stemke-Hale, K., Gonzalez-Angulo, A. M., Lluch, A., Neve, R. M., Kuo, W.-L., Davies, M., Carey, M., Hu, Z., Guan, Y., Sahin, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6854 · Cited by 1,054

Tenets of PTEN Tumor Suppression

Salmena, L., Carracedo, A., & Pandolfi, P. P. (2008) · Cell · doi:10.1016/j.cell.2008.04.013 · Cited by 1,034

Mutant PIK3CA promotes cell growth and invasion of human cancer cells.

Samuels, Y., Diaz, L. A., Schmidt-Kittler, O., Cummins, J. M., DeLong, L., Cheong, I., Rago, C., Huso, D. L., Lengauer, C., Kinzler, K. W., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.05.014 · Cited by 915

MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo

Hirai, H., Sootome, H., Nakatsuru, Y., Miyama, K., Taguchi, S., Tsujioka, K., Ueno, Y., Hatch, H., Majumder, P. K., Pan, B.-S., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1012 · Cited by 860

Molecular alterations of the AKT 2 oncogene in ovarian and breast carcinomas

Bellacosa, A., De Feo, D., Godwin, A. K., Bell, D. W., Cheng, J. Q., Altomare, D. A., Wan, M., Dubeau, L., Scambia, G., Masciullo, V., et al. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910640412 · Cited by 837

Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic

Kang, S., Bader, A. G., & Vogt, P. K. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408864102 · Cited by 823

Oncogenic PI3K deregulates transcription and translation

Bader, A. G., Kang, S., Zhao, L., & Vogt, P. K. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1753 · Cited by 798

NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations

Serra, V., Markman, B., Scaltriti, M., Eichhorn, P. J. A., Valero, V., Guzman, M., Botero, M. L., Llonch, E., Atzori, F., Di Cosimo, S., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1385 · Cited by 787

Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma.

Staal, S. P. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.14.5034 · Cited by 767

Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesis

Jia, S., Liu, Z., Zhang, S., Liu, P., Zhang, L., Lee, S. H., Zhang, J., Signoretti, S., Loda, M., Roberts, T. M., et al. (2008) · Nature · doi:10.1038/nature07091 · Cited by 688

Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

Bendell, J. C., Rodon, J., Burris, H. A., de Jonge, M., Verweij, J., Birle, D., Demanse, D., De Buck, S. S., Ru, Q. C., Peters, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1360 · Cited by 684

Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial

Yao, J. C., Lombard-Bohas, C., Baudin, E., Kvols, L. K., Rougier, P., Ruszniewski, P., Hoosen, S., St. Peter, J., Haas, T., Lebwohl, D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2669 · Cited by 647

Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Hess, G., Herbrecht, R., Romaguera, J., Verhoef, G., Crump, M., Gisselbrecht, C., Laurell, A., Offner, F., Strahs, A., Berkenblit, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.7977 · Cited by 641

Targeting phosphoinositide 3-kinase—Moving towards therapy

Marone, R., Cmiljanovic, V., Giese, B., & Wymann, M. P. (2008) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2007.10.003 · Cited by 548

Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

Herman, S. E. M., Gordon, A. L., Wagner, A. J., Heerema, N. A., Zhao, W., Flynn, J. M., Jones, J., Andritsos, L., Puri, K. D., Lannutti, B. J., et al. (2010) · Blood · doi:10.1182/blood-2010-02-271171 · Cited by 543

AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer

Vasudevan, K. M., Barbie, D. A., Davies, M. A., Rabinovsky, R., McNear, C. J., Kim, J. J., Hennessy, B. T., Tseng, H., Pochanard, P., Kim, S. Y., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.04.012 · Cited by 524

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235

Eichhorn, P. J. A., Gili, M., Scaltriti, M., Serra, V., Guzman, M., Nijkamp, W., Beijersbergen, R. L., Valero, V., Seoane, J., Bernards, R., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1740 · Cited by 499

Balancing Akt with S6K

Manning, B. D. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200408161 · Cited by 476

The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors.

Philp, A., Campbell, I., Leet, C. S. F., Vincan, E., Rockman, S., Whitehead, R. H., Thomas, R. J., & Phillips, W. A. (2001) · PubMed · Cited by 455

Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanisms

Zhao, L., & Vogt, P. K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712169105 · Cited by 437

Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas

Kurose, K., Gilley, K., Matsumoto, S., Watson, P. H., Zhou, X.-P., & Eng, C. (2002) · Nature Genetics · doi:10.1038/ng1013 · Cited by 418

Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation.

Kondapaka, S. B., Singh, S. S., Dasmahapatra, G. P., Sausville, E. A., & Roy, K. (2003) · PubMed · Cited by 407

Pharmacologic Characterization of a Potent Inhibitor of Class I Phosphatidylinositide 3-Kinases

Raynaud, F. I., Eccles, S., Clarke, P. A., Hayes, A., Nutley, B., Alix, S., Henley, A., Di-Stefano, F., Ahmad, Z., Guillard, S., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4615 · Cited by 352

Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin

Yu, K., Toral-Barza, L., Shi, C., Zhang, W.-G., Lucas, J., Shor, B., Kim, J., Verheijen, J., Curran, K., Malwitz, D. J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0299 · Cited by 330

Phosphatidylinositol-3-OH Kinase or RAS Pathway Mutations in Human Breast Cancer Cell Lines

Hollestelle, A., Elstrodt, F., Nagel, J. H. A., Kallemeijn, W. W., & Schutte, M. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0263 · Cited by 320

Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia

Park, S., Chapuis, N., Tamburini, J., Bardet, V., Cornillet-Lefebvre, P., Willems, L., Green, A., Mayeux, P., Lacombe, C., & Bouscary, D. (2010) · Haematologica · doi:10.3324/haematol.2009.013797 · Cited by 306

PIK3CA Mutations and PTEN Loss Correlate with Similar Prognostic Factors and Are Not Mutually Exclusive in Breast Cancer

Pérez-Tenorio, G., Alkhori, L., Olsson, B., Waltersson, M. A., Nordenskjöld, B., Rutqvist, L. E., Skoog, L., & Stål, O. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1609 · Cited by 292

A Vascular Targeted Pan Phosphoinositide 3-Kinase Inhibitor Prodrug, SF1126, with Antitumor and Antiangiogenic Activity

Garlich, J. R., De, P., Dey, N., Su, J. D., Peng, X., Miller, A., Murali, R., Lu, Y., Mills, G. B., Kundra, V., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-0669 · Cited by 279

Mutations in the Phosphatidylinositol-3-Kinase Pathway Predict for Antitumor Activity of the Inhibitor PX-866 whereas Oncogenic Ras Is a Dominant Predictor for Resistance

Ihle, N. T., Lemos, R., Wipf, P., Yacoub, A., Mitchell, C., Siwak, D., Mills, G. B., Dent, P., Kirkpatrick, D. L., & Powis, G. (2009) · Cancer Research · doi:10.1158/0008-5472.can-07-6656 · Cited by 274

A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma

Slomovitz, B. M., Lu, K. H., Johnston, T., Coleman, R. L., Munsell, M., Broaddus, R. R., Walker, C., Ramondetta, L. M., Burke, T. W., Gershenson, D. M., et al. (2010) · Cancer · doi:10.1002/cncr.25515 · Cited by 269

Oncogenic transformation induced by the p110β, -γ, and -δ isoforms of class I phosphoinositide 3-kinase

Kang, S., Denley, A., Vanhaesebroeck, B., & Vogt, P. K. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510772103 · Cited by 267

Perifosine: Update on a novel Akt inhibitor

Gills, J. J., & Dennis, P. A. (2009) · Current Oncology Reports · doi:10.1007/s11912-009-0016-4 · Cited by 221

Status of PI3K inhibition and biomarker development in cancer therapeutics

Markman, B., Atzori, F., Pérez-García, J., Tabernero, J., & Baselga, J. (2010) · Annals of Oncology · doi:10.1093/annonc/mdp347 · Cited by 159

A Phase I Trial of Perifosine (NSC 639966) on a Loading Dose/Maintenance Dose Schedule in Patients with Advanced Cancer

Van Ummersen, L., Binger, K., Volkman, J., Marnocha, R., Tutsch, K., Kolesar, J., Arzoomanian, R., Alberti, D., & Wilding, G. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0406 · Cited by 158

Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment.

Stein, R. C. (2001) · Endocrine Related Cancer · doi:10.1677/erc.0.0080237 · Cited by 127

Loss of class IA PI3K signaling in muscle leads to impaired muscle growth, insulin response, and hyperlipidemia

Luo, J., Sobkiw, C. L., Hirshman, M. F., Logsdon, M. N., Li, T. Q., Goodyear, L. J., & Cantley, L. C. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.04.003 · Cited by 124

First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors.

Burris, H. A., Rodon, J. A., Sharma, S., Herbst, R. S., Tabernero, J. M., Infante, J. R., Silva, A. M. E., Demanse, D., Hackl, W., & Baselga, J. M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3005 · Cited by 109

PTEN and p53: Who will get the upper hand?

Trotman, L. C., & Pandolfi, P. P. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00022-9 · Cited by 105

Mechanism of Constitutive Phosphoinositide 3-Kinase Activation by Oncogenic Mutants of the p85 Regulatory Subunit

Shekar, S. C., Wu, H., Fu, Z., Yip, S.-C., Nagajyothi, Cahill, S. M., Girvin, M. E., & Backer, J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m506005200 · Cited by 85

Molecular Pharmacology and Antitumor Activity of PHT-427, a Novel Akt/Phosphatidylinositide-Dependent Protein Kinase 1 Pleckstrin Homology Domain Inhibitor

Meuillet, E. J., Song, Z., Lemos, R., Ihle, N. T., Kingston, J., Watkins, R., Moses, S. A., Zhang, S., Du‐Cuny, L., Herbst, R. S., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0985 · Cited by 78

A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies.

Edelman, G. M., Bedell, C., Shapiro, G. I., Pandya, S. S., Kwak, E. L., Scheffold, C., Nguyen, L. T., Laird, A., Baselga, J. M., & Rodon, J. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3004 · Cited by 77

Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment

García-Echeverría, C. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.05.099 · Cited by 76

Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma

Bailey, H. H., Mahoney, M. R., Ettinger, D. S., Maples, W. J., Fracasso, P. M., Traynor, A. M., Erlichman, C., & Okuno, S. H. (2006) · Cancer · doi:10.1002/cncr.22308 · Cited by 75

A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotozumab (DALO) in patients (pts) with advanced solid tumors.

Cosimo, S. D., Bendell, J. C., Cervantes, A. M. R., Roda, D., Prudkin, L., Stein, M. N., Leighton-Swayze, A., Song, Y., Ebbinghaus, S., & Baselga, J. M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3008 · Cited by 67

A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors

Wagner, A. J., Hoff, D., LoRusso, P. M., Tibes, R., Mazina, K. E., Ware, J. A., Yan, Y., Derynck, M. K., & Demetri, G. D. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.3501 · Cited by 66

A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumors.

Baselga, J. M., Jonge, M. J. D., Rodon, J. A., Burris, H. A., Birle, D. C., Buck, S. S. D., Demanse, D., Ru, Q. C., Goldbrunner, M., & Bendell, J. C. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3003 · Cited by 53

A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765 (SAR245409), a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced malignancies.

Braña, I., LoRusso, P. M., Baselga, J. M., Heath, E. I., Patnaik, A., Gendreau, S., Laird, A., & Papadopoulos, K. P. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3030 · Cited by 51

First-in-human phase I study exploring three schedules of OSI-027, a novel small molecule TORC1/TORC2 inhibitor, in patients with advanced solid tumors and lymphoma.

Tan, D. S.-W., Dumez, H., Olmos, D., Sandhu, S. K., Hoeben, A., Stephens, A. W., Poondru, S., Gedrich, R. W., Kaye, S. B., & Schöffski, P. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3006 · Cited by 50

Updating progress in sarcoma therapy with mTOR inhibitors

Blay, J. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq307 · Cited by 49

Everolimus in combination with weekly paclitaxel and trastuzumab in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab and taxanes: A multicenter phase II clinical trial.

Dalenc, F., Campone, M., Hupperets, P. S. G. J., O'Regan, R. M., Manlius, C., Vittori, L., Mukhopadhyay, P., Massacesi, C., Sahmoud, T., & André, F. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.1013 · Cited by 48

Interim results from a phase I study of CAL-101, a selective oral inhibitor of phosphatidylinositol 3-kinase p110d isoform, in patients with relapsed or refractory hematologic malignancies.

Furman, R. R., Byrd, J. C., Flinn, I. W., Coutre, S. E., Benson, D. M., Brown, J. R., Kahl, B. S., Wagner‐Johnston, N. D., Giese, N. A., & Yu, A. S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.3032 · Cited by 43

A phase II study of oral mammalian target of rapamycin (mTOR) inhibitor, RAD001 (everolimus), in patients with recurrent endometrial carcinoma (EC)

Slomovitz, B. M., Lu, K. H., Johnston, T., Munsell, M. A., Ramondetta, L. M., Broaddus, R. R., Coleman, R. L., Walker, C., Gershenson, D. M., Burke, T. W., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.5502 · Cited by 39

Abstract 4498: Biological characterization of NVP-BKM120, a novel inhibitor of phosphoinosotide 3-kinase in Phase I/II clinical trials

Voliva, C. F., Pecchi, S., Burger, M. T., Nagel, T., Schnell, C., Fritsch, C. M., Brachmann, S. M., Menezes, D. L. D., Knapp, M. S., Shoemaker, K. R., et al. (2010) · Cancer Research · doi:10.1158/1538-7445.am10-4498 · Cited by 32

Anticorresponding mutations of the KRAS and PTEN genes in human endometrial cancer.

Ikeda, T., Yoshinaga, K., Suzuki, A., Sakurada, A., Ohmori, H., & Horii, A. (2000) · Oncology Reports · doi:10.3892/or.7.3.567 · Cited by 28

Crosstalk Between Pten and Ras Signaling Pathways in Tumor Development

To, M. D., Pérez‐Losada, J., Mao, J., & Balmain, A. (2005) · Cell Cycle · doi:10.4161/cc.4.9.2039 · Cited by 24

Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway

Polivka, J., & Janku, F. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.12.004 · Cited by 765

Gene–Stress–Epigenetic regulation of FKBP5: clinical and translational implications

Zannas, A. S., Wiechmann, T., Gassen, N. C., & Binder, E. B. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2015.235 · Cited by 622

Hepatic mTORC2 Activates Glycolysis and Lipogenesis through Akt, Glucokinase, and SREBP1c

Hagiwara, A., Cornu, M., Cybulski, N., Polak, P., Betz, C., Trapani, F., Terracciano, L., Heim, M. H., Rüegg, M. A., & Hall, M. N. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.03.015 · Cited by 555

Signaling pathways in rheumatoid arthritis: implications for targeted therapy

Ding, Q., Hu, W., Wang, R., Yang, Q., Zhu, M., Li, M., Cai, J., Rose, P., Mao, J., & Zhu, Y. Z. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01331-9 · Cited by 478

Glioblastoma Therapy: Past, Present and Future

Obrador, E., Moreno-Murciano, P., Oriol-Caballo, M., López-Blanch, R., Pineda, B., Gutiérrez-Arroyo, J., Loras, A., Gonzalez-Bonet, L., Martinez-Cadenas, C., Estrela, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052529 · Cited by 271